Evolocumab is prescribed as an adjunct to a low-fat diet and other cholesterol medications in treating patients with high low-density lipoprotein (LDL) cholesterol, total cholesterol, heterozygous ...

A double-blind, randomized, placebo-controlled, multicenter study to evaluate the impact of evolocumab on major cardiovascular events in patients at high cardiovascular risk without prior myocardial ...

Company provided an update on the obicetrapib clinical development program and outlined its strategic priorities for ...

Pfizer is in a three-way fight to bring the first PCSK9 inhibitor to market with Amgen and Sanofi/Regeneron whose respective evolocumab and alirocumab candidates have already been filed for ...